Survival in a Patient with Polycythaemia Vera for over Thirty Years: Implications for Treatment Decisions in Younger Patients

References

• Kurita S. Epidemiological studies of polycythemia vera in Japan. Acta Haematol Jpn 1974; 37: 793–795
   PubMedGoogle Scholar
• Berglund S., Zetterwall O. Incidence of poly-cythaemia vera in a defined population. Eur J Haematol 1992; 48: 20–26
   PubMed Web of Science ®Google Scholar
• Chaiter Y., Brenner B., Aghai E., Tatarsky I. High incidence of myeloproliferative disorders in Ashkenazi Jews in northern Israel. Leak, & Lymphoma 1992; 7: 251–255
   PubMed Web of Science ®Google Scholar
• Najean Y., Mugnier P., Dresch C., Rain J. D. Polycythemia vera in young people: an analysis of 58 cases diagnosed before 40 years. Br J Haematol 1989; 67: 285–291
   Web of Science ®Google Scholar
• Chievitz E., Thiede T. Complications and causes of death in polycythemia vera. Acta Med Scand 1962; 172: 513–523
   PubMed Web of Science ®Google Scholar
• Videbaek A. Polycythemia vera. Course and prognosis. Acta Med Scand 1950; 38: 179–187
   Google Scholar
• Hand H. J., Laszlo H., Laszlo D. C., Jr, Murphy S., Reichert T. A., Tso C. Y., Wasserman L. R. Differentiation between essential thrombocythemia and polycythemia vera with marked thrombocytosis. Am J Hematol 1987; 25: 191–201
   PubMed Web of Science ®Google Scholar
• Berlin N. I. Diagnosis and classification of the polycythemias. Semin Hematol 1976; 12: 339–51
   Web of Science ®Google Scholar
• Pearson T. C., Wetherley-Mein G. Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia. Lancet 1978; 2: 1219–1222
   PubMed Web of Science ®Google Scholar
• Berk P. D., Goldberg J. D., Silverstein M., Weinfeld A., Donovan P. B., Ellis J. T., Landaw S. A., Laszlo J., Najean Y., Pisciota A. V., Wasserman L. R. Increased risk of acute leukaemia in polycythaemia vera associated with chlorambucil treatment. N Engl J Med 1981; 304: 441–447
   PubMed Web of Science ®Google Scholar
• Rozman C., Giralt M., Felihu E., Rubio D., Cortes M. T. Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer 1991; 63: 2658–63
   Web of Science ®Google Scholar
• Najean Y., Rain J. D. The very long-term evolution of polycythemia vera: an analysis of 318 patients initially treated by phlebotomy or 32P between 1969 and 1981. Semin Hematol 1997; 34: 6–16
   PubMed Web of Science ®Google Scholar
• Berk P. D., Goldberg J. D., Donovan P. D., Fruchtman S. M., Berlin N. I., Wassermann L. R. Therapeutic recommendations in polycythemia vera based on the Polycythemia Vera Study Group protocols. Semin Hematol 1986; 23: 132–143
   PubMed Web of Science ®Google Scholar
• Landaw S. A. Acute leukemia in polycythemia vera. Semin Hematol 1986; 23: 156–165
   PubMed Web of Science ®Google Scholar
• Stott H., Fox W., Girling D. J., Stephens R. J., Galton G. A.D. Acute leukaemia after busulphan. Br Med J 1977; 2: 1513–1517
   PubMed Web of Science ®Google Scholar
• Weinfeld A., Westin J., Ridell B., Swolin B. Polycythemia vera terminating in acute leukemia. A clinical, cytogenetic and morphologic study in 8 patients treated with alkylating agents. Scand J Haematol 1977; 19: 255–272
   PubMedGoogle Scholar
• Messinezy M., Pearson T. C., Prochazka A., Wetherley-Mein G. Treatment of primary proliferative polycythaemia by venesection and low dose busulphan: retrospective study from one center. Br J Haematol 1985; 61: 657–666
   PubMed Web of Science ®Google Scholar
• Kaplan M. E., Mack K., Goldberg J. D., Donovan P. B., Berk P. D., Wasserman L. R. Long-term management of polycythemia vera with hydroxyurea: a progress report. Semin Hematol 1986; 23: 167–71
   PubMed Web of Science ®Google Scholar
• Fruchtman S. M., Mack K., Kaplan M. E., Peterson P., Berk P. D., Wasserman L. R. From efficacy to safety: a polycythaemia vera study group report on hydroxyurea in patients with polycythemia vera. Semin Hematol 1997; 34: 17–23
   PubMed Web of Science ®Google Scholar
• Nand S., Messmore H., Gross Fischer S., Lourdes Bird M., Sculz W., Fischer R. I. Leukemic transformation in polycythemia vera: analysis of risk factors. Am J Hematol 1990; 34: 32–36
   PubMed Web of Science ®Google Scholar
• Najean Y., Rain J. D. Treatment of polycythemia vera: use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. Blood 1997; 89: 2319–2327
   PubMed Web of Science ®Google Scholar
• Najean Y., Rain J. D. Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood 1997; 90: 3370–3377
   PubMed Web of Science ®Google Scholar
• Sterkers Y., Preudhomme C., Lai J-L., Demory J-L., Caulier M-T, Wattel E., Bordessoule D., Bauters F., Fenaux P. Acute myeloid leukemia and myelodys-plastic syndromes following essential thrombocythemia treated with hydroxyurea: high prportion of cases with 17p deletion. Blood 1998; 91: 616–622
   PubMed Web of Science ®Google Scholar
• Ludwig H., Cortelezzi A., Van Kamp B. G.K., Polli E., Sheithauer W., Kuzmits R., Linkesch W, Gisslinger H, Sinz-Inger H, Fritz E, Flener R. Treatment with recombinant interferon-alpha-2c: multiple myeloma and thrombocythemia in myeloproliferative diseases. Oncology 1985; 42(suppl 1)19–25
   PubMedGoogle Scholar
• Silver R. T. A new treatment for polycythemia vera: recombinant interferon alfa. Blood 1990; 76: 664–665
   PubMed Web of Science ®Google Scholar
• Reilly J. T., Vellenga E., De Wolf J. Th.M. Interferon treatment in polycythaemia vera. Leuk Lymphoma 1996; 22: 143–148
   PubMed Web of Science ®Google Scholar
• Hino M., Futami E., Okuno S., Miki T, Nishizawa Y., Morii. Possible selective effect of Interferon a-2b on a malignant clone in a case of polycythemia vera. Ann Hematol 1993; 66: 161–162
   PubMed Web of Science ®Google Scholar
• Messora C., Bensi L., Vechi A., Longo R., Giacobbi E, Temperani P., Bevini M., Emilia G., Sacchi S. Cytogenetic conversion in a case of polycythaemia vera treated with interferon-alpha. Br J Haematol 1994; 86: 402–404
   PubMed Web of Science ®Google Scholar
• Anagrelide study group. Anagrelide, a therapy for thrombocythemic states: Experience in 577 patients. Am J Med 1992; 92: 69–76
   PubMed Web of Science ®Google Scholar